Monomethyl auristatin E (MMAE), a potent mitotic inhibitor derived from dolastatin 10, plays a pivotal role in antibody-drug conjugates (ADCs) for cancer therapy. ADCs precisely target cancer cells, minimizing collateral damage. However, ADC development requires thorough pharmacokinetic and safety assessments. Our specialized anti-MMAE antibodies streamline this process, facilitating PK analysis and safety evaluation. These antibodies are crucial tools for optimizing ADCs, ensuring their effectiveness and safety in revolutionizing cancer treatment.